ClinicalTrials.gg

Program

doravirine

Also written as “Doravirine”, “DOR/ISL” and “Doravirine, Tenofovir, Lamivudine”.

Its studies are mostly in Acquired Immunodeficiency Syndrome · HIV Infections · Renal Insufficiency, led by Merck.

Furthest: phase 3, since Oct 23, 201415 company-led studies, 2 open or runningNext primary completion: Nov 12, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck152 open or runningphase 3since Oct 23, 2014Nov 4, 2011Nov 12, 2028phase 2 · NCT04375800

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 4, 2011First study: phase 1 study in HIV-1 InfectionFirst studyNCT01466985 · 18 enrolled
  2. Jun 28, 2012Phase 2 study in HIV InfectionsNCT01632345 · 342 enrolled
  3. Mar 14, 2014Phase 1 study in HIV-1 InfectionNCT02089659 · 16 enrolled
  4. Oct 23, 2014Phase 3 study in HIV-1NCT02275780 · 769 enrolled
  5. Mar 18, 20152 phase 3 studiesNCT02397096, NCT02403674
  6. Sep 11, 2015Phase 1 study in Human Immunodeficiency Virus-1 (HIV-1)NCT02549040 · 16 enrolled
  7. Dec 23, 2015Phase 1 study in Renal InsufficiencyNCT02641067 · 16 enrolled
  8. Jan 8, 2016Phase 2 study in HIV-1NCT02652260 · 86 enrolled
  9. Mar 17, 2016Phase 1 study in Acquired Immunodeficiency SyndromeNCT02715700 · 14 enrolled
  10. Sep 1, 2017Phase 2 study in HIV-1 InfectionNCT03272347 · 123 enrolled · United States, Chile, France and more
  11. Jan 15, 2020Phase 3 study in HIV-1 InfectionNCT04233216 · 35 enrolled · United States, Australia, Canada and more
  12. May 4, 2020Phase 2 study in Acquired Immunodeficiency SyndromeNCT04375800 · 84 planned · United States, Colombia, Dominican Republic and more
  13. Jul 18, 2025Phase 1 study in HealthyNCT07086079 · 12 enrolled · United States
  14. Oct 2, 2026Phase 2 study in HIV InfectionsNCT07862569 · 45 planned

Ahead

  1. Nov 12, 2028Primary completion: phase 2 study in Acquired Immunodeficiency SyndromeNCT04375800
  2. Sep 24, 2029Primary completion: phase 2 study in HIV InfectionsNCT07862569

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Human immunodeficiency virus type 1 reverse transcriptase negative allosteric modulator”ChEMBL 37, by rule

Studies

All 15 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07862569HIV Infections2Not yet recruitingSep 24, 202945
NCT07086079Healthy · United States1CompletedDec 8, 202512
NCT04375800Acquired Immunodeficiency Syndrome · United States, Colombia, Dominican Republic and more2RecruitingNov 12, 202884
NCT04233216HIV-1 Infection · United States, Australia, Canada and more3CompletedNov 21, 202235
NCT03272347HIV-1 Infection · United States, Chile, France and more2CompletedMar 8, 2021123
NCT02715700Acquired Immunodeficiency Syndrome1CompletedJun 13, 201614
NCT02652260HIV-12CompletedAug 14, 201886
NCT02641067Renal Insufficiency1CompletedMay 14, 201616
NCT02549040Human Immunodeficiency Virus-1 (HIV-1)1CompletedDec 24, 201516
NCT02403674Acquired Immunodeficiency Syndrome3CompletedMar 20, 2017734
NCT02397096HIV-1 Infection3CompletedFeb 22, 2018673
NCT02275780HIV-13CompletedSep 29, 2016769
NCT02089659HIV-1 Infection1CompletedMay 12, 201416
NCT01632345HIV Infections2CompletedDec 3, 2014342
NCT01466985HIV-1 Infection1CompletedApr 10, 201218

How it is read

Names in the registry

  • “Doravirine”, 8 entries
  • “DOR/ISL”, 2 entries
  • “Doravirine, Tenofovir, Lamivudine”, 2 entries
  • “Doravirine, Tenofovir, Lamivudine - Blinded”, 1 entry
  • “DOR”, 1 entry

Codes read as this program: MK1439.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.